You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hepatocellular carcinoma (HCC)

Showing 76 - 100 of 9,731
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Cancer, Liver Cirrhoses, Liver Carcinoma Trial in La Jolla (Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid)

Recruiting
  • Liver Cancer
  • +2 more
  • Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
  • La Jolla, California
    University of California, San Diego
Apr 6, 2022

Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

Terminated
Has Results
  • Hepatocellular Carcinoma (HCC)
  • Nancy, France
  • +1 more
Oct 21, 2021

Hepatocellular Carcinoma Trial in Beijing (1mg NWRD06 administered by electroporation, 4mg NWRD06 administered by

Recruiting
  • Hepatocellular Carcinoma
  • 1mg NWRD06 administered by electroporation
  • +2 more
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Oct 15, 2023

Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma Trial in Ann Arbor (drug, device, radiation, diagnostic

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Dec 16, 2021

Hepatocellular Carcinoma Trial in New Taipei City, Hualien City, Taipei (ATL administration)

Recruiting
  • Hepatocellular Carcinoma
  • ATL administration
  • New Taipei City, Taiwan (R. O. C.), Taiwan
  • +3 more
Jun 10, 2022

Thrombocytopenia, Hepatocellular Carcinoma Trial in Guangzhou (Avatrombopag)

Not yet recruiting
  • Thrombocytopenia
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 17, 2023

Carcinoma, Hepatocellular Trial in India (Lenvatinib)

Recruiting
  • Carcinoma, Hepatocellular
  • Bangalore, Karnataka, India
  • +10 more
Feb 1, 2023

Experimental Blood Test to Track Liver Cancer

Recruiting
  • Hepatocellular Carcinoma
    • Philadelphia, Pennsylvania
      Thomas Jefferson University Hospital
    Aug 15, 2022

    Hepatocellular Carcinoma Resectable Trial in Fuzhou (neoadjuvant therapy)

    Not yet recruiting
    • Hepatocellular Carcinoma Resectable
    • neoadjuvant therapy
    • Fuzhou, Fujian, China
      The First Affiliated Hospital of Fujian Medical University
    Aug 19, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guanzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 24, 2023

    Hepatocellular Carcinoma Trial in Changsha (No interventions.)

    Recruiting
    • Hepatocellular Carcinoma
    • No interventions.
    • Changsha, Hunan, China
      Liangrong Shi
    Jun 27, 2023

    Hepatocellular Carcinoma (HCC) Trial in Beijing (Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE))

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Expanded Activated Lymphocytes (EAL)
    • transarterial chemoembolization (TACE)
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Feb 4, 2022

    A Single Center Real-world Study of Donafenib in Treatment of

    Recruiting
    • Donafenib
    • Hepatocellular Carcinoma
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University,
      Mar 17, 2022

      Advanced Hepatocellular Carcinoma (HCC) Trial in Beijing (camrelizumab;Rivoceranib, Rivoceranib, Sorafenib)

      Enrolling by invitation
      • Advanced Hepatocellular Carcinoma (HCC)
      • Beijing, Beijing, China
        Chinese PLA General Hospital
      Oct 21, 2021

      Hepatocellular Carcinoma (HCC) Trial in Japan, Taiwan (ERY974, Tocilicumab, Atezolizumab)

      Recruiting
      • Hepatocellular Carcinoma (HCC)
      • Chiba-shi, Chiba, Japan
      • +5 more
      Jun 22, 2022

      Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

      Recruiting
      • Hepatocellular Carcinoma
      • Guangzhou, Guangdong, China
        Cancer Center Sun Yat-sen University
      May 24, 2023

      Hepatocellular Carcinoma Trial in Louisville (TheraSphere HUD)

      Completed
      • Hepatocellular Carcinoma
      • TheraSphere HUD
      • Louisville, Kentucky
        University of Louisville Hospital / Norton Hospital
      Dec 12, 2021

      Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,

      Not yet recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • I-125 Seeds Brachytherapy in PVTT
      • +2 more
      • (no location specified)
      Aug 14, 2023

      Hepatocellular Carcinoma Trial in Vienna (FMT combined with Atezolizumab plus Bevacizumab)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • FMT combined with Atezolizumab plus Bevacizumab
      • Vienna, Austria
        Medical University of Vienna
      Feb 19, 2023

      Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation Trial in Seoul (Early response evaluation)

      Recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Early response evaluation
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Feb 28, 2023

      Advanced Hepatocellular Carcinoma (HCC) Trial in Beijing (Toripalimab combined with Bevacizumab)

      Active, not recruiting
      • Advanced Hepatocellular Carcinoma (HCC)
      • Toripalimab combined with Bevacizumab
      • Beijing, China
        Beijing Cancer hospital
      Nov 22, 2021

      Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

      Withdrawn
      • Hepatocellular Carcinoma
      • Guangzhou, Guangdong, China
        Cancer Center Sun Yat-sen University
      Jun 1, 2023

      Hepatocellular Carcinoma Trial (The neutrophil-to- lymphocyte ratio, Prognostic nutrition index)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • The neutrophil-to- lymphocyte ratio
      • Prognostic nutrition index
      • (no location specified)
      Jul 28, 2023

      Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • Portal Hypertension
      • TACE ± Systemic therapy
      • Nanjing, China
      • +1 more
      Jan 28, 2023

      Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

      Recruiting
      • Unresectable Hepatocellular Carcinoma
      • Oligometastatic Disease
      • SBRT plus tislelizumab and regorafenib
      • Beijing, Beijing, China
        Peking University Cancer Hospital
      Jun 15, 2023